Sharemaestro company-news research for Edgewise Therapeutics Inc (EWTX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest EWTX news and sentiment

Edgewise Therapeutics Inc

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
Latest weekly closeUSD 39.06week of 9 Oct 2026
Main news subjectMarket update84/100 share of current news
News data statusHealthy41 duplicate stories removed

Current company news

Early balanced news score

23 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone64/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history Market source · 08 Oct 2026 19:11

What supports the score

Direct evidence

23 current stories are mapped specifically to EWTX.

Source breadth

The score uses 5 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.011.

Confidence

Confidence is 16/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news23 company stories
95/100
Story agreement5/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence · gaps mean no reading
17 Sep: 1 stories18 Sep: 1 stories22 Sep: 6 stories23 Sep: 2 stories24 Sep: 1 stories25 Sep: 1 stories29 Sep: 1 stories01 Oct: 2 stories02 Oct: 1 stories03 Oct: 2 stories04 Oct: 1 stories08 Oct: 4 stories 17 Sep: tone 59, 1 stories18 Sep: tone 50, 1 stories22 Sep: tone 53, 6 stories23 Sep: tone 50, 2 stories24 Sep: tone 50, 1 stories25 Sep: tone 50, 1 stories29 Sep: tone 43, 1 stories01 Oct: tone 50, 2 stories02 Oct: tone 50, 1 stories03 Oct: tone 53, 2 stories04 Oct: tone 50, 1 stories08 Oct: tone 50, 4 stories 100500
14 Sep29 Sep13 Oct
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.011 after freshness weighting
Source breadth100
5 independent publishers
Company relevance100
share tied directly to this company
Freshness17
recency-weighted evidence
Agreement95
how closely stories agree
Publisher mix10
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks23 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr 2026: close 34.43, indexed 100.024 Apr 2026: close 31.58, indexed 91.701 May 2026: close 30.61, indexed 88.908 May 2026: close 35.32, indexed 102.615 May 2026: close 33.09, indexed 96.122 May 2026: close 32.7, indexed 95.029 May 2026: close 34.16, indexed 99.205 Jun 2026: close 35.59, indexed 103.412 Jun 2026: close 34.83, indexed 101.219 Jun 2026: close 36.81, indexed 106.926 Jun 2026: close 41.46, indexed 120.403 Jul 2026: close 39.56, indexed 114.910 Jul 2026: close 45.41, indexed 131.917 Jul 2026: close 39.76, indexed 115.524 Jul 2026: close 40.84, indexed 118.631 Jul 2026: close 38.43, indexed 111.607 Aug 2026: close 43.52, indexed 126.414 Aug 2026: close 44.17, indexed 128.321 Aug 2026: close 44.18, indexed 128.328 Aug 2026: close 42.76, indexed 124.204 Sep 2026: close 43.07, indexed 125.111 Sep 2026: close 44.4, indexed 129.018 Sep 2026: close 45.32, indexed 131.625 Sep 2026: close 39.34, indexed 114.302 Oct 2026: close 41.4, indexed 120.209 Oct 2026: close 39.06, indexed 113.4 08 May 2026: news score 50, close 35.32, 1 stories5015 May 2026: news score 50, close 33.09, 1 stories22 May 2026: news score 50, close 32.7, 1 stories29 May 2026: news score 50, close 34.16, 1 stories05 Jun 2026: news score 50, close 35.59, 3 stories5012 Jun 2026: news score 50, close 34.83, 2 stories19 Jun 2026: news score 50, close 36.81, 3 stories26 Jun 2026: news score 52, close 41.46, 9 stories03 Jul 2026: news score 51, close 39.56, 12 stories5110 Jul 2026: news score 51, close 45.41, 17 stories17 Jul 2026: news score 52, close 39.76, 21 stories24 Jul 2026: news score 53, close 40.84, 25 stories31 Jul 2026: news score 49, close 38.43, 35 stories4907 Aug 2026: news score 50, close 43.52, 47 stories14 Aug 2026: news score 49, close 44.17, 62 stories21 Aug 2026: news score 48, close 44.18, 67 stories28 Aug 2026: news score 50, close 42.76, 56 stories5004 Sep 2026: news score 50, close 43.07, 48 stories11 Sep 2026: news score 50, close 44.4, 33 stories18 Sep 2026: news score 52, close 45.32, 13 stories25 Sep 2026: news score 53, close 39.34, 18 stories5302 Oct 2026: news score 51, close 41.4, 20 stories09 Oct 2026: news score 50, close 39.06, 27 stories50 Price index 137.0 110.4 83.7 News score 100 50 0
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
26-week price+13.4%latest close 39.06
News score change+0first to latest comparable week
One-week response-5.7%Price reacting lower
Fair-value position+68.6%Materially above fair value
WeekNews scoreCloseWeekly move
09 Oct 202650USD 39.06-5.7%
02 Oct 202651USD 41.4+5.2%
25 Sep 202653USD 39.34-13.2%
18 Sep 202652USD 45.32+2.1%
11 Sep 202650USD 44.4+3.1%
04 Sep 202650USD 43.07+0.7%
28 Aug 202650USD 42.76-3.2%
21 Aug 202648USD 44.18+0.0%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update5016 stories · 70%
Regulatory and legal503 stories · 13%
Earnings602 stories · 9%
Guidance501 stories · 4%
Analyst action501 stories · 4%

Source mix

Where the evidence comes from

10/100 independence
PR Newswire503 stories · 13%
Investing.com502 stories · 9%
Pluang502 stories · 9%
Yahoo! Finance Canada502 stories · 9%
Stock Titan502 stories · 9%
MT Newswires502 stories · 9%
TradingView651 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences14Financial Markets7Finance2Earnings2Biotech2Unusual Volume1Split1Share Price1Revenue Growth1Options1

Earlier readings

How the score has changed

52 comparable readings · 95 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move-151 to 50 · Broadly stable
Observed range47–5650 is the neutral baseline
Evidence depth24stories at latest stored reading · +7
Confidence15/100Provisional · -9
10 Jul50 neutral13 Oct 15:59
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
13 Oct 15:5950+015/100 (-1)24 (-3)Provisional
08 Oct 23:5950-116/100 (-1)27 (+4)Provisional
04 Oct 23:5951+017/100 (-1)23 (+1)Provisional
03 Oct 23:5951+018/100 (-1)22 (+2)Provisional
02 Oct 23:5951+019/100 (-1)20 (0)Provisional
01 Oct 23:5951+020/100 (-3)20 (+1)Provisional
29 Sep 23:5951-223/100 (-2)19 (+1)Provisional
25 Sep 23:5953-125/100 (-2)18 (+1)Provisional

Evidence behind the direction

What drives this reading?

3 directional stories · 3 publisher groups

Shares of weighted directional evidence in 23 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.

Which subjects lean each way

A subject can carry both supportive and cautious news.

SubjectCautious ← 0 → Constructive
Earnings1 story
0.0%94.9%
Market update2 stories
4.9%0.2%

Each side uses the same scale: 0–94.9% of the retained directional evidence.

Where the influence comes from

94.9%largest publisher share

A concentrated reading can depend heavily on one publisher.

TradingView1 story94.9%
siam.in1 story4.9%
Investing.com Canada1 story0.2%

Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.

Source headlines

The news behind the score

Showing 1-23 of 23

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

Market source
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
08 Oct 2026 19:11
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 5.1d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Investing.com
—Unscored
Market updateNot used in direction

Edgewise doses first patient in heart failure trial

Edgewise Therapeutics Inc. has dosed the first patient in its Phase 2 EQUINOX-HFpEF clinical trial for EDG-15400, targeting adults with symptomatic heart failure with preserved ejection fraction. The trial aims to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynam…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics Inc. has dosed the first patient in its Phase 2 EQUINOX-HFpEF clinical trial for EDG-15400, targeting adults with symptomatic heart failure with preserved ejection fraction. The trial aims to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in approximately 90 participants. EDG-15400 is an oral, selective cardiac sarcomere modulator designed to improve impaired cardiac relaxation, a key characteristic of HFpEF.

Published
08 Oct 2026 15:10
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 5.2d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
Life Sciences
PR Newswire
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
08 Oct 2026 12:00
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 5.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Pluang
—Unscored

Edgewise Therapeutics has initiated its Phase 2 EQUINOX-HFpEF trial, dosing the first patient with EDG-15400, an oral drug designed to improve cardiac relaxation in adults with symptomatic heart failure with preserved ejection fraction (HFpEF). The trial aims to assess the drug's safety, …

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics has initiated its Phase 2 EQUINOX-HFpEF trial, dosing the first patient with EDG-15400, an oral drug designed to improve cardiac relaxation in adults with symptomatic heart failure with preserved ejection fraction (HFpEF). The trial aims to assess the drug's safety, tolerability, and efficacy in approximately 90 patients over 12 weeks, targeting the underlying diastolic dysfunction of this condition. Results and trial design are slated for presentation at the HFSA 2026 meeting in October.

Published
08 Oct 2026 12:30
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 5.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Life SciencesFinancial Markets
Yahoo! Finance Canada
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
04 Oct 2026 18:17
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 9.1d old
Text assessed
Stored headline only
Duplicates
1 consolidated
Simply Wall Street
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
03 Oct 2026 13:26
News subject
Market update
Why this score
Positive valuation view
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 10.3d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Simply Wall St.
—Unscored

Edgewise Therapeutics (EWTX) drew fresh attention after scheduling a special call on September 22, 2026, to walk through the differentiated mechanism of action for its cardiac sarcomere modulator EDG-7500. The special EDG-7500 call lands after a powerful run for Edgewise Therapeutics, wit…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics (EWTX) drew fresh attention after scheduling a special call on September 22, 2026, to walk through the differentiated mechanism of action for its cardiac sarcomere modulator EDG-7500. The special EDG-7500 call lands after a powerful run for Edgewise Therapeutics, with a year to date share price return of 74.32% and a 1 year total shareholder return of 164.54%. However, the 30 day share price return declined 1.38%, suggesting that strong long term momentum may be pausing as traders weigh new clinical signals. Spot 35 healthcare AI stocks that, like Edgewise Therapeutics, a

Published
03 Oct 2026 03:11
News subject
Market update
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 10.7d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
Balance SheetBiotechClinical TrialsHealthcareRevenue GrowthShare Price
Stock Titan
—Unscored

Edgewise Therapeutics director Jonathan C. Fox acquired 308 shares of common stock through restricted stock units on October 1, 2026, as a Quarterly Retainer Award. Following this transaction, his direct holdings increased to 25,141 shares. This insider trade is noted as neutral in sentim…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics director Jonathan C. Fox acquired 308 shares of common stock through restricted stock units on October 1, 2026, as a Quarterly Retainer Award. Following this transaction, his direct holdings increased to 25,141 shares. This insider trade is noted as neutral in sentiment and relates to the company's Outside Directors Compensation Policy.

Published
02 Oct 2026 20:30
News subject
Market update
Why this score
Institutional or insider buying
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 11.0d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
FinanceLife Sciences
PR Newswire
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
01 Oct 2026 12:00
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 12.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Stock Traders Daily
—Unscored

This article from Stock Traders Daily analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting weak near and mid-term sentiment despite a long-term positive outlook. The analysis provides AI-generated trading strategies including position trading, momentum breakout, and risk hedgi…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article from Stock Traders Daily analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting weak near and mid-term sentiment despite a long-term positive outlook. The analysis provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis showing support and resistance levels. The report emphasizes elevated downside risk due to a lack of additional long-term support signals.

Published
01 Oct 2026 11:29
News subject
Guidance
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 12.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Financial MarketsLife Sciences
siam.in
43/100 tone
4.7% of directional evidence Low story strength
Scoring detailsDirect company coverage
Published
29 Sep 2026 07:00
News subject
Market update
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 30/100
30-day weight
4.7% of directional evidence · 14.6d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
MT Newswires
—Unscored

Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription?…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published
25 Sep 2026 17:42
News subject
Analyst action
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 18.1d old
Text assessed
Available headline and article text
Duplicates
3 consolidated
Life Sciences
Moomoo
—Unscored

Edgewise Therapeutics (EWTX) shares are down over 9% and are on track for their largest percentage decrease since December 2025. The stock is currently trading at $13.78, reflecting a 9.39% decline from its previous close. This movement comes during a period where the Nasdaq is also seein…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics (EWTX) shares are down over 9% and are on track for their largest percentage decrease since December 2025. The stock is currently trading at $13.78, reflecting a 9.39% decline from its previous close. This movement comes during a period where the Nasdaq is also seeing declines.

Published
24 Sep 2026 14:57
News subject
Market update
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 19.2d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Financial MarketsLife Sciences
MT Newswires
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
23 Sep 2026 15:41
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.2d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Investing.com
—Unscored
Regulatory and legalNot used in direction

Edgewise unveils mechanism of action for heart drug EDG-7500

Edgewise Therapeutics announced preclinical data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, showing improved cardiac relaxation without affecting systolic function in models and early clinical observations. The company plans to initiate a Phase 3 trial in…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics announced preclinical data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, showing improved cardiac relaxation without affecting systolic function in models and early clinical observations. The company plans to initiate a Phase 3 trial in Q4 2026 for the investigational oral drug, which is designed to address excessive contraction and thickening of the heart's left ventricular wall.

Published
23 Sep 2026 07:49
News subject
Regulatory and legal
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.5d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Financial MarketsLife Sciences
Yahoo! Finance Canada
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
22 Sep 2026 23:11
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.9d old
Text assessed
Stored headline only
Duplicates
1 consolidated
Seeking Alpha
—Unscored

Edgewise Therapeutics, Inc. (EWTX) has published a slide deck discussing the differentiated mechanism of action of its cardiac sarcomere modulator, EDG-7500. This slideshow provides insight into the company's research and development in this area. The information was released on September…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics, Inc. (EWTX) has published a slide deck discussing the differentiated mechanism of action of its cardiac sarcomere modulator, EDG-7500. This slideshow provides insight into the company's research and development in this area. The information was released on September 22, 2026.

Published
22 Sep 2026 15:33
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.2d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Life Sciences
TradingView
65/100 tone

Edgewise Therapeutics' (EWTX) EDG-7500, a cardiac sarcomere modulator, has shown positive results in improving cardiac relaxation and safety in both preclinical and Phase 2 studies for hypertrophic cardiomyopathy. Following these favorable outcomes, the company plans to initiate a Phase 3…

95.1% of directional evidence Medium story strength
Scoring detailsDirect company coverage

Edgewise Therapeutics' (EWTX) EDG-7500, a cardiac sarcomere modulator, has shown positive results in improving cardiac relaxation and safety in both preclinical and Phase 2 studies for hypertrophic cardiomyopathy. Following these favorable outcomes, the company plans to initiate a Phase 3 trial for EDG-7500 in late 2026. This development suggests a significant step forward in the treatment of HCM.

Published
22 Sep 2026 12:48
News subject
Earnings
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 45/100
30-day weight
95.1% of directional evidence · 21.3d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Life Sciences
Stock Titan
—Unscored

Edgewise Therapeutics (EWTX) announced details regarding its cardiac sarcomere modulator, EDG-7500, a first-in-class treatment targeting the regulatory light chain (RLC) for symptomatic heart failure. Preclinical studies and early clinical observations showed EDG-7500 improves cardiac rel…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics (EWTX) announced details regarding its cardiac sarcomere modulator, EDG-7500, a first-in-class treatment targeting the regulatory light chain (RLC) for symptomatic heart failure. Preclinical studies and early clinical observations showed EDG-7500 improves cardiac relaxation while maintaining systolic function. The company screened over 7,000 RLC candidates to identify this molecule, and is preparing to initiate a Phase 3 trial in Q4 2026.

Published
22 Sep 2026 10:48
News subject
Regulatory and legal
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.4d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
EarningsLife Sciences
Pluang
—Unscored

Edgewise Therapeutics announced promising preclinical and early clinical results for EDG-7500, a novel cardiac drug designed to improve heart relaxation in patients with symptomatic hypertrophic cardiomyopathy (HCM) without impairing contraction. The company plans to initiate a Phase 3 tr…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics announced promising preclinical and early clinical results for EDG-7500, a novel cardiac drug designed to improve heart relaxation in patients with symptomatic hypertrophic cardiomyopathy (HCM) without impairing contraction. The company plans to initiate a Phase 3 trial in late 2026 following successful Phase 2 trial outcomes. This first-in-class treatment targets the Regulatory Light Chain and aims to address the genetic heart disease.

Published
22 Sep 2026 10:48
News subject
Earnings
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Financial MarketsLife Sciences
PR Newswire
—Unscored

Edgewise Therapeutics announced the differentiated mechanism of action (MoA) of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain (RLC). Preclinical models show EDG-7500 improves cardiac relaxation while preserving systolic function and cardiac reserve, wi…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Edgewise Therapeutics announced the differentiated mechanism of action (MoA) of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain (RLC). Preclinical models show EDG-7500 improves cardiac relaxation while preserving systolic function and cardiac reserve, with early clinical observations in hypertrophic cardiomyopathy (HCM) patients supporting these findings. The company is hosting a webcast to discuss these data and expects to initiate a Phase 3 trial in Q4 2026 for EDG-7500, an investigational oral therapy for HCM.

Published
22 Sep 2026 07:00
News subject
Regulatory and legal
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.6d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
Life Sciences
Schaeffer's Investment Research
—Unscored
Market updateNot used in direction

Biotech Options Buzz: UTHR, NMRA, EWTX

The article highlights unusual options activity in biotech stocks United Therapeutics (UTHR), Neumora Therapeutics (NMRA), and Edgewise Therapeutics (EWTX). UTHR saw balanced call and put activity after its CEO's family trust sold shares. NMRA experienced high put volume as it hit 52-week…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

The article highlights unusual options activity in biotech stocks United Therapeutics (UTHR), Neumora Therapeutics (NMRA), and Edgewise Therapeutics (EWTX). UTHR saw balanced call and put activity after its CEO's family trust sold shares. NMRA experienced high put volume as it hit 52-week lows, while EWTX saw heavy call volume despite a slight dip from its all-time high.

Published
18 Sep 2026 11:46
News subject
Market update
Why this score
Institutional or insider selling
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 25.4d old
Text assessed
Available headline and article text
Duplicates
3 consolidated
BiotechFinancial MarketsLife SciencesOptionsSplitUnusual Volume
Investing.com Canada
59/100 tone

Edgewise Therapeutics Inc. stock has reached an all-time high of $48.41, marking a significant 1-year surge of 208.11%. This milestone follows the company's sale of its muscular dystrophy business to Servier for up to $2.65 billion and positive analyst coverage from Oppenheimer, Guggenhei…

0.1% of directional evidence Low story strength
Scoring detailsDirect company coverage

Edgewise Therapeutics Inc. stock has reached an all-time high of $48.41, marking a significant 1-year surge of 208.11%. This milestone follows the company's sale of its muscular dystrophy business to Servier for up to $2.65 billion and positive analyst coverage from Oppenheimer, Guggenheim, and RBC Capital. Despite the rapid growth, InvestingPro's Fair Value analysis suggests the stock may be overvalued.

Published
17 Sep 2026 15:58
News subject
Market update
Why this score
Large positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 32/100
30-day weight
0.1% of directional evidence · 26.2d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
EarningsFinanceFinancial MarketsLife SciencesMergers And Acquisitions

Earlier company news

EWTX news archive

122 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 122 older EWTX headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

Showing 1-12 of 12

A news provider linked these stories to EWTX, but the headline and available text are not mainly about Edgewise Therapeutics Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

TradingView
22Sep 2026

HC Wainwright & Co. has reiterated its Buy rating for Edgewise Therapeutics (EWTX), setting a price target of $57.00, which suggests a 25.8% upside from the Sep 18 closing price. The key factors influencing this positive outlook are strong Phase 2 clinical data for EDG-7500 in hypertrophi…

Article detailsWhy it was excluded

HC Wainwright & Co. has reiterated its Buy rating for Edgewise Therapeutics (EWTX), setting a price target of $57.00, which suggests a 25.8% upside from the Sep 18 closing price. The key factors influencing this positive outlook are strong Phase 2 clinical data for EDG-7500 in hypertrophic cardiomyopathy and enhanced financial stability due to a $1.55 billion upfront payment from the Servier transaction, reducing financing risks.

Published
22 Sep 2026 01:56
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
2 consolidated
Financial MarketsLife Sciences
MarketBeat
10Aug 2026
Provider mentionNot included in score

HC Wainwright Has Bearish Forecast for EWTX Q3 Earnings

Article detailsWhy it was excluded
Published
10 Aug 2026 08:00
Provider record
google_news
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
MarketBeat
10Aug 2026
Provider mentionNot included in score

HC Wainwright Has Bearish Forecast for EWTX Q3 Earnings

Article detailsWhy it was excluded
Published
10 Aug 2026 06:51
Provider record
google_news
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
TradingView
02Aug 2026

The article focuses on the enterprise value to EBIT forward metric for Edgewise Therapeutics, Inc. (NASDAQ: EWTX). It appears to be a financial data point or a report available on the TradingView platform, specifically within the financial overview for the company.

Article detailsWhy it was excluded

The article focuses on the enterprise value to EBIT forward metric for Edgewise Therapeutics, Inc. (NASDAQ: EWTX). It appears to be a financial data point or a report available on the TradingView platform, specifically within the financial overview for the company.

Published
2 Aug 2026 19:10
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
Financial MarketsLife Sciences

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context